Massive korean study maps the overlap of heart, kidney, and metabolic diseases

NCT ID NCT07673822

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study examines health data from about 800,000 Korean adults to see how often conditions like obesity, type 2 diabetes, heart disease, chronic kidney disease, and fatty liver occur together. Researchers will analyze national survey and insurance records from 2013 to 2023. No treatments are given—this is an observational study to better understand disease patterns.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could reveal how often these diseases occur together, helping doctors identify high-risk patients earlier.

What could go wrong

This is an observational study using existing data, so it cannot prove cause and effect. Results may not apply to other populations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic kidney disease chronic renal failure syndrome hypertensive disorder inherited lipid metabolism disorder metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder osteoarthritis type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novo Nordisk Pharma Korea, Ltd.

    Seoul, 01000, South Korea